Annual EBITDA
-$21.24 M
-$7.26 M-51.95%
December 31, 2023
Summary
- As of February 7, 2025, DMAC annual EBITDA is -$21.24 million, with the most recent change of -$7.26 million (-51.95%) on December 31, 2023.
- During the last 3 years, DMAC annual EBITDA has fallen by -$8.76 million (-70.26%).
- DMAC annual EBITDA is now -11059.75% below its all-time high of -$190.30 thousand, reached on December 31, 2005.
Performance
DMAC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$6.87 M
-$1.25 M-22.12%
September 30, 2024
Summary
- As of February 7, 2025, DMAC quarterly EBITDA is -$6.87 million, with the most recent change of -$1.25 million (-22.12%) on September 30, 2024.
- Over the past year, DMAC quarterly EBITDA has dropped by -$1.72 million (-33.48%).
- DMAC quarterly EBITDA is now -110954.84% below its all-time high of $6200.00, reached on March 31, 2005.
Performance
DMAC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$24.07 M
-$1.72 M-7.71%
September 30, 2024
Summary
- As of February 7, 2025, DMAC TTM EBITDA is -$24.07 million, with the most recent change of -$1.72 million (-7.71%) on September 30, 2024.
- Over the past year, DMAC TTM EBITDA has dropped by -$4.71 million (-24.32%).
- DMAC TTM EBITDA is now -408133.90% below its all-time high of $5900.00, reached on June 30, 2006.
Performance
DMAC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
DMAC EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -52.0% | -33.5% | -24.3% |
| 3 y3 years | -70.3% | -101.5% | -64.4% |
| 5 y5 years | -283.9% | -101.5% | -64.4% |
DMAC EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -55.9% | at low | -120.2% | at low | -81.7% | at low |
| 5 y | 5-year | -98.2% | at low | -201.1% | at low | -146.7% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | at low | <-9999.0% | at low |
DiaMedica Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$6.87 M(+22.1%) | -$24.07 M(+7.7%) |
| Jun 2024 | - | -$5.63 M(-1.8%) | -$22.35 M(+4.2%) |
| Mar 2024 | - | -$5.73 M(-1.8%) | -$21.46 M(+1.0%) |
| Dec 2023 | -$21.24 M(+52.0%) | -$5.84 M(+13.4%) | -$21.24 M(+9.7%) |
| Sep 2023 | - | -$5.15 M(+8.8%) | -$19.36 M(+11.7%) |
| Jun 2023 | - | -$4.73 M(-14.1%) | -$17.34 M(+8.6%) |
| Mar 2023 | - | -$5.51 M(+39.0%) | -$15.96 M(+14.2%) |
| Dec 2022 | -$13.98 M(+2.6%) | -$3.97 M(+27.1%) | -$13.98 M(+5.5%) |
| Sep 2022 | - | -$3.12 M(-7.1%) | -$13.25 M(-2.1%) |
| Jun 2022 | - | -$3.36 M(-4.9%) | -$13.54 M(-0.0%) |
| Mar 2022 | - | -$3.53 M(+9.0%) | -$13.54 M(-0.6%) |
| Dec 2021 | -$13.62 M(+9.2%) | -$3.24 M(-5.0%) | -$13.62 M(-7.0%) |
| Sep 2021 | - | -$3.41 M(+1.5%) | -$14.64 M(+0.8%) |
| Jun 2021 | - | -$3.36 M(-7.0%) | -$14.52 M(+5.2%) |
| Mar 2021 | - | -$3.61 M(-15.2%) | -$13.80 M(+10.7%) |
| Dec 2020 | -$12.47 M(+16.4%) | -$4.26 M(+29.6%) | -$12.47 M(+15.7%) |
| Sep 2020 | - | -$3.29 M(+24.7%) | -$10.78 M(+9.1%) |
| Jun 2020 | - | -$2.64 M(+15.5%) | -$9.89 M(+1.3%) |
| Mar 2020 | - | -$2.28 M(-11.2%) | -$9.76 M(-8.9%) |
| Dec 2019 | -$10.72 M(+93.7%) | -$2.57 M(+7.5%) | -$10.72 M(+6.2%) |
| Sep 2019 | - | -$2.39 M(-4.7%) | -$10.09 M(+12.3%) |
| Jun 2019 | - | -$2.51 M(-22.6%) | -$8.98 M(+9.5%) |
| Mar 2019 | - | -$3.24 M(+66.7%) | -$8.20 M(+48.3%) |
| Dec 2018 | -$5.53 M(+29.5%) | -$1.94 M(+51.0%) | -$5.53 M(+16.5%) |
| Sep 2018 | - | -$1.29 M(-25.6%) | -$4.75 M(+13.6%) |
| Jun 2018 | - | -$1.73 M(+203.0%) | -$4.18 M(+19.0%) |
| Mar 2018 | - | -$571.00 K(-50.8%) | -$3.51 M(-17.0%) |
| Dec 2017 | -$4.27 M(+83.8%) | -$1.16 M(+61.5%) | -$4.23 M(+15.5%) |
| Sep 2017 | - | -$719.40 K(-32.2%) | -$3.66 M(-5.1%) |
| Jun 2017 | - | -$1.06 M(-17.7%) | -$3.86 M(+16.9%) |
| Mar 2017 | - | -$1.29 M(+117.4%) | -$3.30 M(+42.0%) |
| Dec 2016 | -$2.32 M(+51.7%) | -$593.10 K(-35.3%) | -$2.32 M(-1.2%) |
| Sep 2016 | - | -$916.60 K(+82.4%) | -$2.35 M(+44.0%) |
| Jun 2016 | - | -$502.60 K(+61.0%) | -$1.63 M(+11.6%) |
| Mar 2016 | - | -$312.20 K(-49.8%) | -$1.46 M(-7.8%) |
| Dec 2015 | -$1.53 M(-67.9%) | -$622.30 K(+214.9%) | -$1.59 M(-7.6%) |
| Sep 2015 | - | -$197.60 K(-40.6%) | -$1.72 M(-28.5%) |
| Jun 2015 | - | -$332.40 K(-23.8%) | -$2.40 M(-27.6%) |
| Mar 2015 | - | -$436.00 K(-42.1%) | -$3.32 M(-32.2%) |
| Dec 2014 | -$4.77 M | -$752.40 K(-14.8%) | -$4.90 M(-8.1%) |
| Sep 2014 | - | -$882.80 K(-29.3%) | -$5.33 M(-7.1%) |
| Jun 2014 | - | -$1.25 M(-37.9%) | -$5.74 M(-6.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$2.01 M(+69.6%) | -$6.14 M(-2.0%) |
| Dec 2013 | -$6.30 M(-18.4%) | -$1.19 M(-7.9%) | -$6.26 M(-16.6%) |
| Sep 2013 | - | -$1.29 M(-21.9%) | -$7.51 M(-8.2%) |
| Jun 2013 | - | -$1.65 M(-22.8%) | -$8.17 M(-3.8%) |
| Mar 2013 | - | -$2.14 M(-12.2%) | -$8.50 M(+11.6%) |
| Dec 2012 | -$7.72 M(+77.8%) | -$2.43 M(+24.4%) | -$7.61 M(+17.0%) |
| Sep 2012 | - | -$1.96 M(-0.8%) | -$6.51 M(+11.6%) |
| Jun 2012 | - | -$1.97 M(+57.6%) | -$5.83 M(+22.1%) |
| Mar 2012 | - | -$1.25 M(-5.7%) | -$4.77 M(+5.3%) |
| Dec 2011 | -$4.34 M(+70.1%) | -$1.33 M(+3.7%) | -$4.53 M(+8.9%) |
| Sep 2011 | - | -$1.28 M(+39.5%) | -$4.16 M(+32.1%) |
| Jun 2011 | - | -$917.00 K(-9.3%) | -$3.15 M(+10.1%) |
| Mar 2011 | - | -$1.01 M(+6.0%) | -$2.86 M(+25.0%) |
| Dec 2010 | -$2.55 M(+7.7%) | -$954.50 K(+255.5%) | -$2.29 M(+22.0%) |
| Sep 2010 | - | -$268.50 K(-57.2%) | -$1.88 M(-13.8%) |
| Jun 2010 | - | -$626.70 K(+42.8%) | -$2.18 M(+8.7%) |
| Mar 2010 | - | -$438.90 K(-19.1%) | -$2.00 M(-8.6%) |
| Dec 2009 | -$2.37 M(+42.9%) | -$542.40 K(-4.6%) | -$2.19 M(+21.5%) |
| Sep 2009 | - | -$568.60 K(+25.7%) | -$1.80 M(-6.5%) |
| Jun 2009 | - | -$452.40 K(-28.0%) | -$1.93 M(-9.1%) |
| Mar 2009 | - | -$628.10 K(+307.1%) | -$2.12 M(+10.5%) |
| Dec 2008 | -$1.66 M(-27.6%) | -$154.30 K(-77.7%) | -$1.92 M(-19.5%) |
| Sep 2008 | - | -$693.40 K(+7.6%) | -$2.38 M(+15.2%) |
| Jun 2008 | - | -$644.30 K(+50.9%) | -$2.07 M(-15.1%) |
| Mar 2008 | - | -$427.10 K(-31.0%) | -$2.44 M(+11.9%) |
| Dec 2007 | -$2.29 M(+192.3%) | -$619.10 K(+63.1%) | -$2.18 M(+22.5%) |
| Sep 2007 | - | -$379.60 K(-62.5%) | -$1.78 M(+8.5%) |
| Jun 2007 | - | -$1.01 M(+503.3%) | -$1.64 M(+162.6%) |
| Mar 2007 | - | -$167.80 K(-23.6%) | -$624.60 K(+37.6%) |
| Dec 2006 | -$783.90 K(+311.9%) | -$219.60 K(-8.6%) | -$453.90 K(+93.7%) |
| Sep 2006 | - | -$240.20 K(-8106.7%) | -$234.30 K(-4071.2%) |
| Jun 2006 | - | $3000.00(+3.4%) | $5900.00(+103.4%) |
| Mar 2006 | - | $2900.00(-53.2%) | $2900.00(-101.1%) |
| Dec 2005 | -$190.30 K(-69.8%) | - | - |
| Mar 2005 | - | $6200.00(-103.1%) | -$270.00 K(-6.3%) |
| Dec 2004 | -$630.30 K | - | - |
| Dec 2004 | - | -$200.90 K(+1213.1%) | -$288.30 K(+74.3%) |
| Sep 2004 | - | -$15.30 K(-74.5%) | -$165.40 K(-2.2%) |
| Jun 2004 | - | -$60.00 K(+395.9%) | -$169.20 K(+42.3%) |
| Mar 2004 | - | -$12.10 K(-84.5%) | -$118.90 K(+11.3%) |
| Dec 2003 | - | -$78.00 K(+308.4%) | -$106.80 K(+270.8%) |
| Sep 2003 | - | -$19.10 K(+96.9%) | -$28.80 K(+196.9%) |
| Jun 2003 | - | -$9700.00 | -$9700.00 |
FAQ
- What is DiaMedica Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for DiaMedica Therapeutics?
- What is DiaMedica Therapeutics annual EBITDA year-on-year change?
- What is DiaMedica Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for DiaMedica Therapeutics?
- What is DiaMedica Therapeutics quarterly EBITDA year-on-year change?
- What is DiaMedica Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for DiaMedica Therapeutics?
- What is DiaMedica Therapeutics TTM EBITDA year-on-year change?
What is DiaMedica Therapeutics annual EBITDA?
The current annual EBITDA of DMAC is -$21.24 M
What is the all time high annual EBITDA for DiaMedica Therapeutics?
DiaMedica Therapeutics all-time high annual EBITDA is -$190.30 K
What is DiaMedica Therapeutics annual EBITDA year-on-year change?
Over the past year, DMAC annual EBITDA has changed by -$7.26 M (-51.95%)
What is DiaMedica Therapeutics quarterly EBITDA?
The current quarterly EBITDA of DMAC is -$6.87 M
What is the all time high quarterly EBITDA for DiaMedica Therapeutics?
DiaMedica Therapeutics all-time high quarterly EBITDA is $6200.00
What is DiaMedica Therapeutics quarterly EBITDA year-on-year change?
Over the past year, DMAC quarterly EBITDA has changed by -$1.72 M (-33.48%)
What is DiaMedica Therapeutics TTM EBITDA?
The current TTM EBITDA of DMAC is -$24.07 M
What is the all time high TTM EBITDA for DiaMedica Therapeutics?
DiaMedica Therapeutics all-time high TTM EBITDA is $5900.00
What is DiaMedica Therapeutics TTM EBITDA year-on-year change?
Over the past year, DMAC TTM EBITDA has changed by -$4.71 M (-24.32%)